Current Research Studies
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of ARD-101 for the Treatment of Hyperphagia in Patients with Prader -Willi Syndrome
AVK-101-301
What is the goal of the study?
The primary efficacy objective is to evaluate the effect of ARD-101 on hyperphagia-related behavior in patients with PWS as measured by total score of the 9-item Hyperphagia Questionnaire for Clinical Trials (9-item HQ-CT). The primary safety objective, assessed throughout the study, is to evaluate the safety and tolerability of ARD-101 in patients with PWS.
Who can participate in the study?
Please contact the study team listed below to learn more.